tiprankstipranks
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
US Market
MAZE
Maze Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see MAZE full AI Analyst Report?

Maze Therapeutics, Inc. (MAZE) Stock News & Sentiment

99 Followers
MAZE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
MAZE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3d ago
MAZE
Maze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline
Premium
Ratings
Maze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline
8d ago
MAZE
Maze Therapeutics prices $150 million equity offering
Premium
Company Announcements
Maze Therapeutics prices $150 million equity offering
28d ago
8K
MAZE
MAZE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
MAZE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
MAZE
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
Premium
Ratings
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
2M ago
MAZE
Maze Therapeutics adds Neil Kumar to board leadership
Premium
Company Announcements
Maze Therapeutics adds Neil Kumar to board leadership
2M ago
8K
MAZE
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
Premium
Ratings
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
2M ago
MAZE
More MAZE News >

MAZE News on the Web

LifeSci Capital Remains a Buy on Maze Therapeutics, Inc. (MAZE)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Shoulder Innovations, Inc. (SI), Maze Therapeutics, Inc. (MAZE) and PACS Group Inc (PACS)
TipRanks News
Bullish
Wells Fargo Remains a Buy on Maze Therapeutics, Inc. (MAZE)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE) and Anixa Biosciences (ANIX)
TipRanks News
Neutral
Wedbush Sticks to Their Buy Rating for Maze Therapeutics, Inc. (MAZE)
TipRanks News
Bullish
Maze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline
TipRanks News
Bullish
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Neutral
J.P. Morgan Remains a Buy on Maze Therapeutics, Inc. (MAZE)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
MAZE
Sector Average
Media Buzz
This Week4 articles
Weekly Average3 articles
News Sentiment
This Week99%
Sector Average76%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MAZE’s Media Buzz Sentiment?
4 articles about MAZE were published this week. In an average week, 3 articles are published.
    What is MAZE’s weekly average amount of articles?
    In an average week, 3 articles about MAZE are published.
      What is MAZE’s News Sentiment?
      99% of articles about MAZE were positive this week, compared to its sector average of 76%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        CGENCompugen
        PROKProKidney
        ROIVRoivant Sciences
        Showing the stocks with the most bullish news sentiment over the past week